Abstract: Anaplastic lymphoma kinase (ALK) fusion is commonly observed in lung adenocarcinoma, with an incidence rate of 5%-7%. Due to the tumor heterogeneity in advanced non-small cell lung cancer, ALK fusion can also occur in lung squamous cell carcinoma. A multidisciplinary team (MDT) combines various professional opinions and evidence-based medical principles to provide personalized treatment recommendations, particularly for complex cases. This study presents the MDT diagnostic and treatment approach for a patient with lung squamous cell carcinoma with an ALK mutation. Following initial diagnosis at stage ⅢB, the patient exhibited rapid disease progression with liver and brain metastases after sequence chemoradiotherapy. After genetic testing revealed ALK fusion, the patient was treated with the ALK inhibitor, lorlatinib, which resulted in tumor regression and a persistent partial response.